Balci, HaticeKoş???us, AydinKaygusuz, İkbal CekmenKöşüş, NerminEser, Ayla AçarAltindiş, Ayşe2025-10-242025-10-2420151300-03062146-9024https://doi.rog/10.5336/gynobstet.2014-38756https://hdl.handle.net/20.500.12899/3205Sentinel lymph node (SLN), where the primary tumoral lymphatic flow firstly ends is the place with the highest possibility of tumoral involvement in case of metastasis from the primary tumor. Therefore; according to the lymphatic mapping hypothesis, if the sentinel node is negative in terms of metastasis, non-sentinel nodes are also expected to be negative. Several techniques have been reported to identify the sentinel nodes. These are blue dye labeling, radio labeling and combined labeling that comprise sequential application of blue dye and technetium (tc) labeling. Blue dye is the general procedure when injected into damaged tissue intraoperativly to distinguish the tumor tissue. SLN dissection application is used in vulva and cervix cancers more commonly in gynecologic cancers. For this purpose, in cases where tc-labeled nanocolloid is used, SLN detection rate has been found 100%. It has been reported that SLN detection rate was 80-86% in cervical cancer, 50-80% in endometrial cancer and a little lower than those in vulva cancer. The method of SLN is consolidating its role in the diagnosis of vulvar and cervical cancer day by day. However, the most frequently encountered problems in the application of the SLN are the cases which found negative for metastasis in histopathological examination but understood to have micro level metastases at ultra-staging. The main prognostic factors in vulvar cancer is the nodal metastasis that independent from the primary tumor size. The conformity of routine use of SLN dissection without complementary lymphadenectomy is still controversial because inguinal region metastases is fatal in patients with vulvar carcinoma. However, most modern and promising future method is considering to be SLN biopsy. More studies are required for vulvar melanoma, vaginal, ovarial and endometrial cancers. © 2021 Elsevier B.V., All rights reserved.trinfo:eu-repo/semantics/openAccessEndometrial neoplasmsSentinel lymph node biopsyUterine cervical neoplasmsVaginal neoplasmsVulvar neoplasmsArticle10.5336/gynobstet.2014-387562531871942-s2.0-84938238336N/A